Navigation Links
Leerink in Medical News

Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference

SAN FRANCISCO, May 13 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference on Wednesday, May 20 in New York. Dr. Hung will pr...

Caliper Life Sciences to Present at Leerink Swann's 3rd Annual Life Science Tools Roundtable Conference

HOPKINTON, Mass., July 31 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP ) today announced that its presentation at the Leerink Swann's Life Science Tools Roundtable Conference in Boston, Massachusetts, will be webcast on Thursday, August 7 at 12:50 p.m. EDT. Kevin Hrusov...

Genomic Health to Participate in Leerink Swann Roundtable Conference

REDWOOD CITY, Calif., March 28 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that Steven Shak, M.D., Genomic Health's Chief Medical Officer, will participate in Leerink Swann's Roundtable Conference, Bugs and Drugs: The Future of Molecular Diagnostics, in New ...

Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that the Company will present at the Leerink Swann "Bugs and Drugs: The Future of Molecular Diagnostics Roundtable Conference" in New York on April 3, 2008 at approximately 1:20 p.m. Eastern T...

BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference

FRANKLIN LAKES, N.J., March 26 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it would present at the Leerink Swann Molecular Diagnostics Roundtable Conference on Thursday, April 3, 2008 at 10:10 a.m. (ET). ...

MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

...2009, subject to satisfaction of customary closing conditions. Deutsche Bank Securities Inc. is acting as Sole Book-Running Manager for the offering. leerink Swann LLC is acting as Co-Lead Manager and Wedbush PacGrow Life Sciences is acting as Co-Manager. MAP Pharmaceuticals has filed a registration ...

Orexigen(R) Therapeutics Prices Public Offering of Common Stock

...t to satisfaction of customary closing conditions. leerink Swann LLC is acting as sole book-running manager f...ies of which may be obtained, when available, from leerink Swann LLC , Attention: Syndicate Department, One F...l Street, 37th Fl., Boston, MA 02110 or by calling leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814...

Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock

.... All of the shares are being offered by Orexigen. leerink Swann LLC is acting as sole book-running manager f...tus relating to this offering may be obtained from leerink Swann LLC , Attention: Syndicate Department, One F...l Street, 37th Fl., Boston, MA 02110 or by calling leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814...

Inverness Medical Innovations, Inc. Announces Offering of $200 Million of Senior Subordinated Notes

...vestment Bank, Goldman, Sachs & Co. and Banc of America Securities LLC will act as joint book-running managers for the offering. Canaccord Adams, leerink Swann and Stifel Nicolaus will serve as co-managers. The offering will be made under Inverness' shelf registration statement on Form S-3 filed wi...

Alsius Corporation Announces Agreement to Sell Assets to ZOLL Medical Corporation

...g to the business, other intangibles, inventories and fixed assets. The closing of the transaction is subject to customary closing conditions. leerink Swann LLC acted as exclusive financial advisor and delivered an opinion to the board of Alsius as to the fairness of the transaction. William W...
Leerink in Medical Technology

Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon's product candidate AL-108 significantly reduces th...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

... combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner." leerink Swann LLC acted as exclusive placement agent and exclusive financial advisor in connection with the transaction. About Light Sciences Oncology Lig...
Leerink in Biological Technology

Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference

SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at...

Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Presid...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Frida...

Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference

WESTFORD, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO ), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that the company will present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Con...

Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock

...d Exchange Commission a prospectus supplement with respect to the offering. leerink Swann LLC is acting as sole book-running manager for the offering. ...pplement and accompanying prospectus may be obtained, when available, from leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37(th) Floo...

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

...and commissions and estimated expenses). leerink Swann LLC acted as sole book-running manager for t...g prospectus, copies of which may be obtained from leerink Swann LLC , Attention: Syndicate Department, One F...l Street, 37th Fl., Boston, MA 02110 or by calling leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814...

Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

...20 a.m. ET Deutsche Bank Securities 34th Annual Healthcare Conference InterContinental Boston Tuesday, May 19, 2009 4:35 p.m. ET leerink Swann Novel Cancer Therapeutics: Oncology Roundtable The Roosevelt Hotel, New York City Wednesday, May 20, 2009 10:30 a.m. ET The ...

Dendreon Reports First Quarter 2009 Financial Results

...of America / Merrill Lynch 2009 Health Care Conference on May 12, 2009 Deutsche Bank 34th Annual Healthcare Conference on May 19, 2009 leerink Swann Novel Cancer Therapeutics: Roundtable Conference on May 20, 2009 About Dendreon Dendreon Corporation is a biotechnolog...

Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock

...before deducting the placement agent's fee and estimated offering expenses. leerink Swann LLC served as sole placement agent for the offering. Trout Capital pr... may be obtained at the SEC's website at http://www.sec.gov or by calling leerink Swann, toll free, at 1-800-808-7525, Ext. 4556. About Pharmasset P...

Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering

...lose on or about July 21, 2008, subject to satisfaction of customary closing conditions. Lazard Capital Markets LLC served as lead placement agent and leerink Swann LLC served as co-placement agent for the offering. Jazz Pharmaceuticals intends to use the net proceeds from this offering primarily to fund c...
Other Tags
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Seniors are more easily ... a new study finds. "Almost any type of ... the age of 25 on," study co-author Randi Martin, ... university news release. However, Martin said, this study ... processing in older adults compared with younger adults. ...
(Date:7/25/2014)... As reported by People Magazine in the article ... and Getting Sober (7/15), one of the most popular ... out to the public about his personal transformation. Now, two ... admits that moving on with his life was a challenge. ... drugs in 2012 and even spent some time in rehab. ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 AttorneyOne.com, a ... the latest information from the FDA on Ibuprofen and ... 21, that one lot of Ibuprofen and one lot of ... due to mislabeled packaging. Oxcarbazepine is used for the ... , The reason for the recall is that ...
(Date:7/25/2014)... July 25, 2014 Parker Waichman LLP, ... of consumers comments on a recent tobacco lawsuit in ... smoker $23.6 billion in punitive damages. Cynthia Robinson brought ... cigarettes. The case is Cynthia Robinson v. R.J. Reynolds ... Florida First Circuit Court, Escambia County, Florida; Case Number ...
(Date:7/25/2014)... Drexel University College of Medicine ... FACP, has been appointed vice dean for education, effective October ... The Commonwealth Medical College, where she is currently chair of ... and professor of medicine. , As a member of ... had a major role in many aspects of the development ...
Breaking Medicine News(10 mins):Health News:Distractions Seem More Troublesome With Age 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Creating sustainable STEM teacher preparation programs 2
Other Contents